Control of toxoplasmosis by inducing Th1 helper cells

1)猫IL-12基因的克隆与表达IL-12具有增强NK细胞活性、刺激CTL活性和诱导INF-γ产生的作用，因此IL-12被认为是Th 1辅助细胞源性免疫应答的关键细胞因子。克隆、表达并鉴定了猫IL-12 p35和p40亚基的全长cDNA。重组猫IL-12具有IFN-γ诱导活性和CTL刺激活性。弓形虫免疫显性抗原P22（SAG 2）、P30（SAG 1）、P54（ROP 2）和SRS 1的编码基因。以RH株的cDNA为模板，PCR扩增弓形虫的cDNA，并在E. coli细胞。重组抗原免疫小鼠产生部分保护性免疫。3）表达弓形虫抗原基因的重组猫疱疹病毒的构建。表达弓形虫P22、P30、P54、SRS 1免疫原性抗原的重组猫疱疹病毒1型（FHV-1）。结果表明，重组抗原与弓形虫天然抗原相似。弓形虫的结构和抗原性。表达IL-12的FHV-1的构建正在进行中。用FHV-1/TgP 22、FHV-1/TgP 30、FHV-1/TgP 54和FHV-1/SRS 1免疫猫，可产生抗弓形虫的部分保护性免疫。弓形虫感染，分别。我们的下一步将是对猫进行免疫试验，以检查FHV-1/IL-12诱导抗弓形虫病有效免疫的效力。

1) Cloning and expression of feline IL-12 geneIt is known that IL-12 enhances NK activity, stimulates CTL activity and induces INF-γ production, and therefore IL-12 is considered as a key cytokine in Th1 helper cell-derived immune responses. A full length cDNA of feline IL-12 p35 and p40 subunits was cloned, expressed and characterized. The recombinant feline IL-12 has both INF-γ -inducing activity and CTL-stimulating activity.2) Cloning and expression of the immunodominant antigen genes of T. gondiiThe genes encoding immunodominant antigens, P22 (SAG2), P30 (SAG1), P54 (ROP2), and SRS1 of T. gondii were PCR-amplified using cDNA from RH strain as templates, and expressed in E. coli cells. Mice immunized with recombinant antigens produced a partial protective immunity against T. gondii challenge infections.3) Construction of recombinant feline herpesviruses expressing the antigen genes of T. gondiiRecombinant feline herpesvirus type 1 (FHV-1) expressing immunogenic antigens (P22, P30, P54, SRS1) of T. gondii were constructed, and demonstrated that the recombinant antigens were similar to the native antigens from T. gondii in structure and antigenicity. Construction of FHV-1 expressing IL-12 is under way.4) Protective effects of recombinant FHV-1 expressing T. gondii antigens against challenge infection in catsCats immunized with FHV-1/TgP22, FHV-1/TgP30, FHV-1/TgP54, and FHV-1/SRS1 produced a partial protective immunity against T. gondii infections, respectively. Our next step will be immunization trials with cats to check the potency of the FHV-1/IL-12 to induce effective immunity against toxoplasmosis.